102 related articles for article (PubMed ID: 12568610)
1. Synthesis and NMR structure of p41icf, a potent inhibitor of human cathepsin L.
Chiva C; Barthe P; Codina A; Gairí M; Molina F; Granier C; Pugnière M; Inui T; Nishio H; Nishiuchi Y; Kimura T; Sakakibara S; Albericio F; Giralt E
J Am Chem Soc; 2003 Feb; 125(6):1508-17. PubMed ID: 12568610
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S.
Guncar G; Pungercic G; Klemencic I; Turk V; Turk D
EMBO J; 1999 Feb; 18(4):793-803. PubMed ID: 10022822
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory fragment from the p41 form of invariant chain can regulate activity of cysteine cathepsins in antigen presentation.
Mihelic M; Dobersek A; Guncar G; Turk D
J Biol Chem; 2008 May; 283(21):14453-60. PubMed ID: 18362148
[TBL] [Abstract][Full Text] [Related]
4. Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L.
Bevec T; Stoka V; Pungercic G; Dolenc I; Turk V
J Exp Med; 1996 Apr; 183(4):1331-8. PubMed ID: 8666891
[TBL] [Abstract][Full Text] [Related]
5. Potential sites for processing of the human invariant chain by cathepsins D and E.
Kageyama T; Yonezawa S; Ichinose M; Miki K; Moriyama A
Biochem Biophys Res Commun; 1996 Jun; 223(3):549-53. PubMed ID: 8687433
[TBL] [Abstract][Full Text] [Related]
6. The proteolytic environment involved in MHC class II-restricted antigen presentation can be modulated by the p41 form of invariant chain.
Fineschi B; Sakaguchi K; Appella E; Miller J
J Immunol; 1996 Oct; 157(8):3211-5. PubMed ID: 8871612
[TBL] [Abstract][Full Text] [Related]
7. Immunochemical localisation of cathepsin S, cathepsin L and MHC class II-associated p41 isoform of invariant chain in human lymph node tissue.
Zavasnik-Bergant V; Sekirnik A; Golouh R; Turk V; Kos J
Biol Chem; 2001 May; 382(5):799-804. PubMed ID: 11517933
[TBL] [Abstract][Full Text] [Related]
8. Thyroglobulin type-I-like domains in invariant chain fusion proteins mediate resistance to cathepsin L digestion.
Hitzel C; Kanzler H; König A; Kummer MP; Brix K; Herzog V; Koch N
FEBS Lett; 2000 Nov; 485(1):67-70. PubMed ID: 11086167
[TBL] [Abstract][Full Text] [Related]
9. The p41 fragment story.
Turk D; Guncar G; Turk V
IUBMB Life; 1999 Jul; 48(1):7-12. PubMed ID: 10791909
[TBL] [Abstract][Full Text] [Related]
10. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading.
Riese RJ; Wolf PR; Brömme D; Natkin LR; Villadangos JA; Ploegh HL; Chapman HA
Immunity; 1996 Apr; 4(4):357-66. PubMed ID: 8612130
[TBL] [Abstract][Full Text] [Related]
11. Cathepsin L regulates CD4+ T cell selection independently of its effect on invariant chain: a role in the generation of positively selecting peptide ligands.
Honey K; Nakagawa T; Peters C; Rudensky A
J Exp Med; 2002 May; 195(10):1349-58. PubMed ID: 12021314
[TBL] [Abstract][Full Text] [Related]
12. The SEP domain of p47 acts as a reversible competitive inhibitor of cathepsin L.
Soukenik M; Diehl A; Leidert M; Sievert V; Büssow K; Leitner D; Labudde D; Ball LJ; Lechner A; Nägler DK; Oschkinat H
FEBS Lett; 2004 Oct; 576(3):358-62. PubMed ID: 15498563
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory p41 isoform of invariant chain and its potential target enzymes cathepsins L and H in distinct populations of macrophages in human lymph nodes.
Zavasnik-Bergant V; Schweiger A; Bevec T; Golouh R; Turk V; Kos J
Immunology; 2004 Jul; 112(3):378-85. PubMed ID: 15196205
[TBL] [Abstract][Full Text] [Related]
14. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis.
Tolosa E; Li W; Yasuda Y; Wienhold W; Denzin LK; Lautwein A; Driessen C; Schnorrer P; Weber E; Stevanovic S; Kurek R; Melms A; Bromme D
J Clin Invest; 2003 Aug; 112(4):517-26. PubMed ID: 12925692
[TBL] [Abstract][Full Text] [Related]
15. One of two unstructured domains of Ii becomes ordered in complexes with MHC class II molecules.
Jasanoff A; Song S; Dinner AR; Wagner G; Wiley DC
Immunity; 1999 Jun; 10(6):761-8. PubMed ID: 10403651
[TBL] [Abstract][Full Text] [Related]
16. Purification of the complex of cathepsin L and the MHC class II-associated invariant chain fragment from human kidney.
Ogrinc T; Dolenc I; Ritonja A; Turk V
FEBS Lett; 1993 Dec; 336(3):555-9. PubMed ID: 8282126
[TBL] [Abstract][Full Text] [Related]
17. The p41 isoform of invariant chain is a chaperone for cathepsin L.
Lennon-Duménil AM; Roberts RA; Valentijn K; Driessen C; Overkleeft HS; Erickson A; Peters PJ; Bikoff E; Ploegh HL; Wolf Bryant P
EMBO J; 2001 Aug; 20(15):4055-64. PubMed ID: 11483509
[TBL] [Abstract][Full Text] [Related]
18. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding.
Kropshofer H; Vogt AB; Hämmerling GJ
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8313-7. PubMed ID: 7667286
[TBL] [Abstract][Full Text] [Related]
19. The slow-binding inhibition of cathepsin K by its propeptide.
Billington CJ; Mason P; Magny MC; Mort JS
Biochem Biophys Res Commun; 2000 Oct; 276(3):924-9. PubMed ID: 11027570
[TBL] [Abstract][Full Text] [Related]
20. Asparagine endopeptidase is not essential for class II MHC antigen presentation but is required for processing of cathepsin L in mice.
Maehr R; Hang HC; Mintern JD; Kim YM; Cuvillier A; Nishimura M; Yamada K; Shirahama-Noda K; Hara-Nishimura I; Ploegh HL
J Immunol; 2005 Jun; 174(11):7066-74. PubMed ID: 15905550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
